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Two years experience with quality assurance
protocol for patient related Rapid Arc treatment






Purpose: To verify the dose distribution and number of monitor units (MU) for dynamic treatment techniques like
volumetric modulated single arc radiation therapy - Rapid Arc - each patient treatment plan has to be verified
prior to the first treatment. The purpose of this study was to develop a patient related treatment plan verification
protocol using a two dimensional ionization chamber array (MatriXX, IBA, Schwarzenbruck, Germany).
Method: Measurements were done to determine the dependence between response of 2D ionization chamber
array, beam direction, and field size. Also the reproducibility of the measurements was checked. For the patient
related verifications the original patient Rapid Arc treatment plan was projected on CT dataset of the MatriXX and
the dose distribution was calculated. After irradiation of the Rapid Arc verification plans measured and calculated
2D dose distributions were compared using the gamma evaluation method implemented in the measuring
software OmniPro (version 1.5, IBA, Schwarzenbruck, Germany).
Results: The dependence between response of 2D ionization chamber array, field size and beam direction has
shown a passing rate of 99% for field sizes between 7 cm × 7 cm and 24 cm × 24 cm for measurements of single
arc. For smaller and larger field sizes than 7 cm × 7 cm and 24 cm × 24 cm the passing rate was less than 99%.
The reproducibility was within a passing rate of 99% and 100%. The accuracy of the whole process including the
uncertainty of the measuring system, treatment planning system, linear accelerator and isocentric laser system in
the treatment room was acceptable for treatment plan verification using gamma criteria of 3% and 3 mm, 2D
global gamma index.
Conclusion: It was possible to verify the 2D dose distribution and MU of Rapid Arc treatment plans using the
MatriXX. The use of the MatriXX for Rapid Arc treatment plan verification in clinical routine is reasonable. The
passing rate should be 99% than the verification protocol is able to detect clinically significant errors.
Introduction
Rapid Arc radiotherapy technology from Varian Medical
Systems is one of the most complex delivery systems cur-
rently available, and achieves an entire intensity-
modulated radiation therapy (IMRT) treatment in a
single gantry rotation around the patient. Three dynamic
parameters can be continuously varied to create IMRT
dose distributions: speed of rotation, beam shaping aper-
ture and delivery dose rate [1]. The variation of three
dynamic parameters is used to cover the planning target
volume with clinical acceptable dose and to spare the
organs at risk (OAR) and normal tissue. Due to the volu-
metric single arc the treatment can be performed in less
time than IMRT treatment. Some studies compared the
dose to OAR, healthy tissue sparing, and target coverage
of Rapid Arc to conventional forwardly planed radiother-
apy technique, fixed field IMRT, Helical Tomotherapy,
and Intensity Modulated Proton therapy [2-17].
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management of cancer is the correct calculation of the
dose distribution and the correct treatment delivery.
Gagne at al. have shown that the calculation of the dose
distribution can be performed with a clinical acceptable
accuracy using the algorithm AAA (anisotropic analyti-
cal algorithm [18,19]) with a resolution of 2.5 mm or
better [20]. Ling et al. have shown that the DMLC
movement, variable dose-rates and gantry speeds can be
precisely controlled during Rapid Arc [21].
In opposite to 3D conventional treatment techniques
in dynamic treatment techniques the verification of the
MU is much more complex. Therefore the dose distri-
bution is verified using 2D or 3D measuring devices like
2D ionization chamber arrays or phantoms equipped
with radiographic films. In the past some investigations
were done to ascertain the potential of different types of
2D ionization chambers for IMRT verification measure-
ments [22-36].
The purpose of this study was to analyze the potential
of the MatriXX for patient related verification of Rapid
Arc treatment plans. Therefore some preparing mea-
surements were done. We determined the dependence
between response of the MatriXX, beam direction, and
field size. Also we repeated 2D dose distribution mea-
surements ten times and compared each measurement
with the first one to check the reproducibility of the
method.
Materials and methods
Two dimensional ionization chamber array
The two dimensional ionization chamber array consists
of a 32 × 32 matrix of 1024 parallel plate ionization
chambers. The ionization chambers are arranged in a
square of 24 cm × 24 cm as active measuring area. Each
chamber has 0.4 cm diameter and 0.55 cm height. The
distance between each ionization chamber is 0.75 cm
from centre to centre of adjacent chambers. The sensi-
tive volume of each single ionization chamber is
0.07 cm
3. Each of the 1024 independent ionization cham-
bers is read out with a custom microelectronics chip.
Preparing measurements
To analyse the potential of the MatriXX for verification
of Rapid Arc treatment plans two measurement series
were accomplished. First the dependence of MatriXX
response of beam direction and field size were analysed.
Therefore the MatriXX was irradiated with unblocked
photon arc fields with field sizes of 3 cm × 3 cm, 5 cm ×
5c m ,1 0c m×1 0c m ,2 0c m×2 0c m ,2 4c m×2 4c m ,
a n d3 0c m×3 0c m .T h eu n b l o c k e dp h o t o na r cf i e l d s
were irradiated using a full rotation of the gantry around
the MatriXX (start angle 181°, stop angle 179°, counter
clockwise, Varian scale IEC 601). Second the
reproducibility was checked for field size of 10 cm ×
10 cm. Therefore the measurement was compared with
repeated measurements with the same setup using the
gamma evaluation method with the criteria 3% und
2 mm, no threshold, 2D global gamma index [37]. The
measurement was repeated ten times. The measurements
took place at the Clinac 2300 C/D (Varian Medical Sys-
tem, Palo Alto, CA, USA). For all measurements a
photon energy of 6 MVphotons was used. 500 MU were
applied for all measurements. The MatriXX was used in
the acquisition mode “Movie Mode”. The sampling time
was set to 200 ms, the maximum number of sample to 5,
and the number of movie images to 2000. The measured
matrix was interpolated linear to 1 mm and was scaled
relative to maximum. All measurements were normalized
to maximum dose. For the treatment the verification
plan has to be prepared within the record and verify sys-
tem. The manufacturer declared a warm up time of 15 min
and pre-irradiation with 10 Gy before measurement.
Patient treatment plans
Different patient treatment plans were used, 53 treat-
ment plans of the head region, 68 treatment plans of
the head and neck region, and 312 treatment plans of
the pelvis region. A total of 433 different treatment
plans in complexity with 598 arcs were measured and
analyzed. For treatment of gliomas a total dose (TD) of
6 0G yw i t has i n g l ed o s e( S D )o f2 . 0G yw a su s e d .T h e
other treatments in the head regions were applied with
aT Do f3 0G y( S D2 . 7 5G y )t ot h ew h o l eb r a i nw i t ha
c o n c o m i t a n tb o o s tw i t haT Do f4 5G y( S D3 . 7 5G y ) .
Additional the boost plans of cerebral metastases with a
TD of 9 Gy or 15 Gy (SD 2.5 Gy or 3.0 Gy, respectively)
are analysed. Head and neck cancer patients were trea-
ted using an integrated protocol with a TD 54 Gy (SD
1.8 Gy) to lymph node regions, which were possible
involved, and a TD 57.6 Gy (SD 1.92 Gy) to lymph
node regions, which are involved with a high possibility.
The region of the primary tumour was treated with a
TD of 66 Gy (SD 2.2 Gy) for treatment with a curative
intent and with a TD of 62.4 Gy (SD 2.08 Gy) for adju-
vant intent. In the pelvis region patient with rectal can-
cer (neo adjuvant treatment with TD 50.4 Gy, SD
1.8 Gy), cervical cancer (adjuvant treatment with TD
50.4 Gy, SD 1.8 Gy) and prostate cancer were analysed.
The TD for patient with prostate cancer differed
b e t w e e n6 0G yt o7 2G y( S D2 . 0G y ) .S o m ep a t i e n t
received additional and concomitant treatment of the
lymph node region with a TD of 45 Gy (SD 1.8 Gy). For
all treatment plans photon energy of 6 MVPhotons with
the dose rate of 600 MU/min (800 MU/min for field
size smaller than 15 cm × 15 cm and energy mode 6
MVphotons SRS) were used. The treatment plans were
optimized for single or double arc delivery (s. table 1 for
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delivery the gantry rotated clockwise around the patient,
for double arc delivery first clockwise and second coun-
ter clockwise. The start angle for single arc in clockwise
direction ranged between 181° and 270°, and the stop
angle between 90° and 179°. The start angle for the sec-
ond arc in counter clockwise direction ranged between
90° and 179°, and the stop angle for the second arc in
counter clockwise direction between 181° and 270°. For
each treatment plan 177 control points were set. The
dose distribution for all plans were calculated with
Eclipse treatment planning system (TPS) from Varian
Medical Systems, version 8.5; using AAA algorithm with
a grid size of 0.2 cm × 0.2 cm × 0.2 cm. The AAA is a
3D pencil Beam convolution/superposition algorithm
that uses separate Monte Carlo derived modelling for
primary photons, scattered extra-focal photons, and
electrons scattered from the beam limiting devices
[18,19]. The treatment couch structures (exact couch,
Varian Medical Systems, Palo Alto, CA, USA) were con-
sidered during the calculation process.
Verification treatment plans
The patient Rapid Arc treatment plan was projected on
the CT scan of the MatriXX including 4 cm polymethyl-
methacrylate (PMMA) above and underneath the active
measuring area to account for build up and backscatter.
The isocenter was positioned at the centre of the active
measuring area. For calculation of the dose distribution
the TPS Eclipse using the AAA algorithm, version 8.5
with a grid size of 0.2 cm × 0.2 cm × 0.2 cm was used.
The treatment couch structures were considered during
the calculation process.
Analysis
The 2D dose distribution in the active measuring area in
the frontal CT slice of the verification plan was exported
with the resolution of 1 mm and imported into the
software OmniPro. The measured dose distribution was
generated during single or double rotation of the gantry
around the MatriXX. The acquisition mode, scaling
mode, sampling time, number of samples, number of
movie images and interpolation algorithm was set as
described above. The analysis was made using gamma
evaluation method [37] to compare measured and calcu-
lated dose distribution. The gamma evaluation criteria
w e r e3 %a n d3m m ,n ot h r e s h o l d ,2 Dg l o b a lg a m m a
index. For the analysis of the gamma evaluation result
the histogram of the gamma evaluation was displayed.
The histogram of the gamma evaluation plotted the
number of pixel against the gamma value. The total
number of pixel with a gamma value above 1 was
divided by the total number of pixel within the region
of interest (ROI). The ROI was set to field size +1 cm.
Results
Preparing measurements
The MatriXX response agrees within 99% of pixel with
gamma evaluation value beneath 1 for field sizes
between 7 cm × 7 cm and 24 cm × 24 cm for measure-
ments of single arc. For smaller and larger field sizes
then 7 cm × 7 cm and 24 cm × 24 cm the response was
less than 99% of the pixel with gamma evaluation value
beneath 1. The passing rate was 93.8% for field size
3 cm × 3 cm, 98.3% for field size 5 cm × 5 cm, and
82.2% for field size 30 cm × 30 cm, respectively. The
reproducibility was within a passing rate of 99% and
100% (range 99.4% and 100.0%).
Verification treatment plans
The mean treatment time was 1.05 min for all patients,
ranging from 0.78 min to 1.56 min. We do not use full
rotation of the gantry around the patient for all treat-
ments. If possible we spared the treatment couch and
OAR, which have low dose tolerance like lenses. The
system tried to move the gantry with maximum speed if
Table 1 Results
region number of monitor units Treatment time [sec] passing rate PTV [ml] field size cm
head 341 ± 221 0.99 ± 0.12 99.88 ± 0.19 388.2 ± 539.6 14.7 ± 5.5
head and neck 191 ± 102 0.85 ± 0.01 99.80 ± 0.39 477.8 ± 429.8 20.1 ± 4.8
prostate 300 ± 123 1.00 ± 0.06 99.54 ± 0.21 717.2 ± 617.5 15.6 ± 4.9
abdomen 231 ± 28 0.92 ± 0.05 99.76 ± 0.32 1032.6 ± 500.8 20.7 ± 2.3
range
head 118 - 1717 0.78 - 1.09 99.11 - 100.00 7.9 - 1895.0 7.0 - 24.0
head and neck 118 - 693 0.84 - 0.85 97.04 - 100.00 22.3 - 1916.3 7.0 - 24.0
prostate 129 - 906 0.91 - 1.08 98.84 - 100.00 37.6 - 3559.8 7.2 - 24.0
abdomen 195 - 274 0.89 - 0.96 99.15 - 100.00 894.5 - 2140.6 19.0 - 24.0
The columns show (left to right) the region of the localization of the PTV, the mean MU used for the treatment and its standard deviation, the mean treatment
time per arc and its standard deviation, the mean passing rate and its standard deviation, the mean volume of the PTV and its standard deviation, and the mean
field size by jaws and its standard deviation. The first three rows give the mean results for the different regions. The last three rows show the range of each
region.
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into the given position that fast and the MU could be
d e l i v e r e dt h a tf a s t .I ft h ed o s er a t er e a c h e dt h em a x i -
mum of 600 MU/min (800 MU/min for field sizes smal-
ler than 15 cm × 15 cm and energy mode 6 MVphotons
SRS) the gantry speed was reduced.
After measurement, both - measured and calculated
dose distribution - were compared using gamma evalua-
tion method implemented in the software OmniPro.
Using the histogram the distribution of the gamma eva-
luation was displayed. The results of the ratio of the
number of pixel beneath the gamma evaluation value of
1 divided by the total number of pixel within the ROI is
shown in table 1.
The passing rate was between 99.0% and 100.0% in
431 of 433 cases. In two cases - one head and neck and
o n ep r o s t a t ec a s e-t h ep a s s i n gr a t ew a s9 7 . 7 %a n d
98.8%, respectively. In 53 head cases the mean passing
rate was 99.88% ± 0.19% with PTV volume sizes ranging
between 7.9 ml and 1895.0 ml and the resulting square
field sizes between 7.0 cm and 24.0 cm. The mean pas-
sing rate in 68 head and neck cases was 99.80% ± 0.39%
with PTV volume size ranging between 22.3 ml and
1916.3 ml and the resulting square field sizes between
7.0 cm and 24.0 cm. For 312 cases in pelvis region the
mean passing rate was 99.54% ± 0.21% with PTV
volume sizes ranging between 37.6 ml and 3559.8 ml
and the resulting square field sizes between 7.2 cm and
24.0 cm.
To check if the verification protocol is able to detect
clinically significant errors the original patient Rapid
Arc treatment plan was manipulated. Therefore the
MLC position (Millennium 120 Multi leaf collimator,
Varian Medical Systems, Palo Alto, CA, USA) was chan-
ged and the dose distribution was calculated with the
changed MLC position. To change the MLC position
single leafs has to be set to another position at all 177
control points using the MLC movement tool of the
TPS. The 2D dose distribution was measured and com-
pared with the original, unchanged 2D dose distribution.
If the MLC position was changed in a way that the dose
distribution was changed clinically significant and there-
fore the probability of toxicity was increased the passing
rate was less than 99% with the settings of the MatriXX
mentioned above (s. figure 1). Clinically significant
means increasing the dose to the OAR higher than the
given limits by Emami et al. [38], and decreasing the
dose to the PTV according to ICRU-50 report.
Uncertainty budget
Since the comparison of measured and calculated 2D
dose distribution was considered as the end result, the
following sources contributing to the overall uncertainty
of the result were identified:
￿ MatriXX measurement method
￿ Monitor output fluctuation of treatment machine
￿ Dose calculation of the treatment planning system
￿ Specifications of treatment machine
In our study, the uncertainty components for MatriXX
measurement method had to be taken into account due
to positioning of MatriXX using the isocentric laser sys-
tem in treatment room, the broadening of the penumbra
due to the volume effect of the ionization chambers
which act as low pass filter, and an additional compo-
nent for response of ionization chamber reading. In
addition, the daily monitor output fluctuation of the
treatment machine varies up to 0.75% (daily measure-
ments with ionization chamber). The manufacturer of
the treatment machine specifies dose stability during
gantry rotation to 2%; accuracy of gantry, collimator,
and couch rotation to 0.75 mm; and accuracy of MLC
positioning to 1 mm. For the accuracy of the dose cal-
culation, the manufacturer specifies 1.0% for unblocked
photon fields. The uncertainty of the treatment
machine’s basic data measurements had to be taken into
consideration within 2 mm. The consideration of 2 mm
contained the exact positioning of the ionization cham-
ber during basic data measurements for the TPS before
clinical operation. The different contributions are listed
in table 2.
The common used gamma evaluation criteria 3% and
3m mw e r ea s s u m e dt ob es u f f i c i e n tf o rt h ee v a l u a t i o n
of the measured and calculated 2D dose distribution in
the active measurement area of the MatriXX.
Discussion
We investigated this study to generate a patient related
verification procedure for Rapid Arc treatment plans.
Before we started to generate the verification protocol
we investigated measurements to analyse the potential
of the MatriXX for unblocked photon arc fields. The
MatriXX response showed good agreements between
calculated and measured dose distribution for field sizes
o f7c m×7c ma n d2 4c m×2 4c mw i t hap a s s i n gr a t e
between 99% and 100%. Higher aberrations were found
for smaller field sizes than 7 cm × 7 cm and for larger
field sizes than 24 cm × 24 cm. During Rapid Arc verifi-
cation measurement we measured the whole dose distri-
bution which consists of 177 control points (177 beam
directions with different MLC shapes and gantry speeds
between each beam direction). 2/177 beams irradiated
perpendicular through the MatriXX. In addition a range
of control points irradiated near lateral through the
MatriXX. The advantage of the MatriXX is cylindrical
parallel plate chambers. Our results showed good agree-
ment between measured and calculated dose distribu-
tion in the active measurement area. We assume that
the TPS considered the beam angle dependence of the
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the angular dependence is clinically tolerable for field
sizes between 7 cm × 7 cm and 24 cm × 24 cm.
In our study we projected the patient Rapid Arc treat-
ment plan with its MLC shape, gantry speed and dose
rate parameters on the CT dataset of the MatriXX
including 4 cm build up and 4 cm backscatter material
as well as the treatment couch structures. The electron
density of the different parts of the MatriXX as well as
the treatment couch was considered during dose distri-
bution calculation. Using the TPS Eclipse V. 8.5 and
above it is possible to insert Varian treatment couch
types to the CT dataset. The absorption of the treat-
ment couch is considered by giving the system Houns-
field Units (HU) for each part of the treatment couch
like couch top and rails. The correct HU were deter-
mined by comparison of measured values using an ioni-
zation chamber and calculated values by TPS [for more
Figure 1 a) Example of measured 2D dose distribution of a head and neck case. The MLC positions were changed in the region of the
spinal cord to got higher dose to the spinal cord which could not be clinically tolerated. b) Passing rate against the maximum dose to the
spinal cord of the same head and neck case. 4 Rapid Arc treatment plans were generated by changing the MLC positions. The changed Rapid
Arc treatment plans were compared to the original Rapid Arc treatment plan. The original Rapid Arc treatment plan showed a passing rate of
99.3%. The lines indicate the in our clinic tolerated limits: 45 Gy maximum dose to the spinal cord and 99% passing rate.
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Page 5 of 8details s. [39]]. In the past several studies were published
which showed that the treatment couch attenuation is
up to 3% for beam direction 180° and up to 9% for obli-
que beam directions [40-45] and needs to be considered.
According to the study of Ling et al. [21] quality
assurance of treatment machine especially for Rapid Arc
was done monthly as well as weekly measurements of
absolute dose of arc fields and dynamic MLC fields
using ionization chamber. Due to our quality assurance
we could be sure that the treatment machine delivered
complex Rapid Arc plans correctly if the 2D dose distri-
bution was within the passing rate of 99% using the pre-
sented method.
Wolfsberger et al. presented recently their method for
IMRT and Rapid Arc quality assurance [36]. They
showed in their study that the MatriXX response is
dependent on beam directions. The dependency was 7%
to 11% for perpendicular and oblique beam directions
and need to be corrected. They suggest correcting the
angular dependence using correction factors for each
beam angle. Popple et. al. published their first experi-
ence with patient related quality assurance of dynamic
treatment techniques (IMRT and Rapid Arc) of 52 cases
[46]. In their study they considered the angular depen-
dence of the 2D ionization chamber array as well. In
opposite to Wolfsberger et. al. they corrected the angu-
lar dependence using a special formed phantom (Multi-
cube, IBA, Schwarzenbruck) which considered for the
angular dependence. Van Esch et. al. considered the
angular dependence of the 2D ionization chamber array
in the same way using a special formed phantom [27].
Our presented method allows the quality assurance of
Rapid Arc treatment plans prior to treatment. The
method was tested for quality assurance of 433 treat-
ment plans with different complexity. We projected the
patient treatment plan on the CT dataset of the
MatriXX including the treatment couch structures and
calculated the dose distribution using the AAA algo-
rithm. Due to our results we conclude that the angular
dependence may be considered correctly/clinically toler-
able in the TPS if the CT dataset of the measurement
device including 4 cm build up and 4 cm backscatter
material, the treatment couch structures, and the AAA
a l g o r i t h mw i t hag r i ds i z eo f0 . 2c m×0 . 2c m×0 . 2c m
are used for field sizes between 7 cm × 7 cm and
24 cm × 24 cm.
In different studies [for example [27,36], and [46]] the
angular dependence of 2D ionization chamber array are
determined and considered in different ways. All studies
showed that with their presented method the angular
dependence was considered correctly to use the mea-
surement device for the quality assurance of dynamic
treatment techniques. In our study we considered for
the angular dependence by calculation of the dose distri-
bution on the CT dataset of the MatriXX, by consider-
ing the treatment couch structures during the
calculation process, by using all beam directions of all
177 control points, by using 4 cm PMMA for build up
and 4 cm PMMA for backscatter, and by using the
AAA algorithm with a grid size of 0.2 cm × 0.2 cm ×
0.2 cm. Due to this setup the effect of angular depen-
dence of the MatriXX is clinically tolerable for 2D dose
distribution comparison using the gamma evaluation
method with criteria 3% and 3 mm.
To characterize the angular sensitivity of the MatriXX
we have done measurements before starting to imple-
ment a verification protocol for patient related Rapid
Arc treatment plan verifications. We have used a differ-
ent way to characterize the angular dependence and
field size dependence of the MatriXX. We combined
both end results in one test to get one combined end
result. We felt that this method is adequate because
during the Rapid Arc treatment and the measurement
of the 2D dose distribution using the MatriXX the
dependence of angular beams and dependence of field
sizes are combined as well. Different studies have shown
dependence of beam angle and treatment couch consid-
ering as single end result, but did not combine different
end results. By combining different end results in one
test setup the potential of the measurement device can
be seen easily for the setup which will be used during
quality assurance measurements.
Herzen et al. analysed the dose and energy dependence
of the MatriXX. They showed that the detector’s response
was linear with dose and energy independent [30].
Table 2 Uncertainty components for the verification
method
Uncertainty budget
Components for measurement Uncertainty
MatriXX Ionization chambers 2%
broadening of penumbra (low pass filter) 1 mm
positioning of IMRT-MatriXX 1 mm
monitur output fluctuation 0.75%
dose stability during gantry rotation 2%
stability gantry, collimator, and couch rotation 0.75 mm
MLC positioning 1 mm
Total 2.9%, 1.9 mm
Components for calculation Uncertainty
dose calculation of treatment planning system 1%
Basic data measurements 2 mm
Total 1%, 2 mm
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detector arrays was to ease the two dimensional verifica-
tions of fields with complex shapes and large gradients
[26]. Since two dimensional detector arrays have been
developed, these systems have been used for quality con-
trol and verification of IMRT. The results of some studies
were in good agreement with calculations performed with
the TPS and with the standard dosimetric tools, i.e., films
or various point dose detectors [22-24].
The MatriXX has the potential for Rapid Arc treatment
plan verifications. If the MLC position was changed in a
way that the dose distribution was changed clinically sig-
nificant, the passing rate was less than 99% with gamma
criteria 3% and 3 mm for the presented method (s.
figure 1). For a passing rate below 99% the optimization
and calculation of the patient Rapid Arc treatment plan
has to be redone using other constraints for the optimi-
zation process to smooth the dose gradients.
The measured and calculated doses were normalized
relative to dose maximum. By the normalization process
the deviation in the gamma evaluation method were
suppressed in low dose regions. It has to be taken into
account that OAR are presented in the low dose region
and the passing of the gamma evaluation criteria 3%
and 3 mm may result in larger deviation in this regions.
However in the most cases the gradients and modula-
tions were not really high using the treatment protocols
for the presented cases as described above and Rapid
Arc treatments. Therefore the normalization method
could be tolerated.
We set the passing rate to 99% than the verification
protocol is able to detect clinically significant errors as
the manipulated measurements showed. Some of the
irradiated ionization chambers of the MatriXX may have
significant larger deviations. This larger deviation may
lead to patient mistreatment. It has to be taken into
account that the mistreatment was true for the actual
fraction. However the patient was setup several times
for the treatment and the single larger deviations will be
spread.
For IMRT treatment plans the manufacturer has
implemented the use of the portal imager as measuring
device. It is quite easy to verify IMRT treatment plans
with portal dosimetry because of no need to set up an
external measuring device. Therefore the setup error has
not to be taken into account using the laser system in
the treatment room. The manufacturer is questioned to
provide the portal dosimetry system for Rapid Arc veri-
fications as well.
Conclusion
The method is easy to implement into clinical routine.
Verifying 2D dose distribution and MU with the
MatriXX for Rapid Arc treatment plans is reasonable.
The passing rate should to be 99% to detect clinically
significant errors using the gamma criteria 3% and
3 mm, 2D global gamma index.
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